RBL 001/RBL 002

Drug Profile

RBL 001/RBL 002

Alternative Names: MERIT; RB0001; RB_0001; RBL-001/RBL-002; RBL-002/RBL-001

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNTech; Ribological
  • Developer Ribological
  • Class Cancer vaccines; RNA vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in Austria (Intralymphatic, Injection)
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Malignant-melanoma in Germany (Intralymphatic, Injection)
  • 24 Jul 2016 Phase I development is ongoing in Germany and Austria for Malignant melanoma (Late-stage disease)(Intralymphatic, Injection) (NCT02035956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top